Simone F.
- Country
- Italy
- Department
- Ematologia Universitaria
Research Overview
- Glofitamab Versus Investigator's Choice in Patients with Relapsed or Refractory Mantle Cell Lymphoma
- Phase II Multicenter Study of Glofitamab Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma After CAR‑T Cell Failure
- Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapy
Data & Insights
Has run more than one trial at 85 of 241 partner sites.
Specializations
Lymphoma Treatment Research
Specializes in investigating innovative therapeutic approaches for various types of lymphomas, with particular emphasis on B-cell lymphomas and their treatment pathways.
- Follicular Lymphoma Management
- Mantle Cell Lymphoma Therapies
- Diffuse Large B-Cell Lymphoma Treatment
Focuses on developing combination therapies using novel agents with established treatments.
Novel Therapeutic Combinations
Explores the integration of targeted therapies with conventional treatment modalities, including immunotherapy and chemotherapy combinations.
- Antibody-Based Treatments
- BTK Inhibitor Therapies
- Immunochemotherapy Protocols
Investigates treatment strategies for both newly diagnosed and relapsed/refractory patients.
Advanced Hematologic Oncology
Conducts research in progressive treatment approaches for challenging hematologic conditions, particularly in resistant disease settings.
- Consolidation Therapies
- Combined Modality Treatments
- Rituximab-Based Protocols
Evaluates treatment efficacy in various lymphoma subtypes and stages.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.